Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : BFI-751
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Avance Clinical
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Phase I Study of BFI-751 Compared With EU and US-STELARA® in Healthy Adults
Details : BFI-751 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Psoriasis.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 13, 2021
Lead Product(s) : BFI-751
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Avance Clinical
Deal Size : Inapplicable
Deal Type : Inapplicable